^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Inflammatory biomarkers for prediction of tumor responses and adverse events in non-small cell lung cancer patients treated with anti-PD-1 inhibitor.

Published date:
05/16/2018
Excerpt:
Peripheral blood samples were taken from NSCLC patients before nivolumab treatment and every 6-12 weeks from the patients who continued nivolumab treatment...The plasma levels of GM-CSF and Chitinase 3-like-1 before treatment were significant correlated with PFS (P= 0.005 and P= 0.007, respectively).
DOI:
10.1200/JCO.2018.36.15_suppl.e21050